The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases

Autor: Ozge Gumusay, Laura A. Huppert, Spencer C. Behr, Hope S. Rugo, M.D.

Publikováno v: Breast, Vol 63, Iss , Pp 149-156 (2022)

Patients with metastatic breast cancer are at high risk for developing vertebral compression fractures due to underlying bone metastases and bone density loss. Vertebral augmentation techniques including percutaneous vertebroplasty and percutaneous b

Externí odkaz: https://doaj.org/article/88fc0d6b14d04a3687c3c86713696c2d

Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy

Autor: Mark Jesus M. Magbanua, Ozge Gumusay, Razelle Kurzrock, Laura J. van ‘t Veer, Hope S. Rugo

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Liquid biopsy biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are noninvasive diagnostics that could complement predictive and prognostic tools currently used in the clinic. Recent trials of immunotherapy have sh

Externí odkaz: https://doaj.org/article/e747fad8174441c8b07c1934557ed636

Contralateral Testicular Metastasis of Renal Cell Carcinoma: A Case Report

Autor: Engin Kolukcu, Sahin Kilic, Bekir Süha Parlaktas, Faik Alev Deresoy, Dogan Atilgan, Ozge Gumusay, Nihat Uluocak

Publikováno v: Eurasian Journal of Medicine, Vol 51, Iss 3, Pp 310-312 (2019)

Externí odkaz: https://doaj.org/article/b19e1a13ffc6472ebfbe4f270f523e93

Alpelisib induced interstitial lung disease in a patient with advanced breast cancer

Autor: Aysun Isiklar, Gul Basaran, Beyza Sepin, Ozge Gumusay, Ayse Sesin Kocagoz, Caglar Cuhadaroglu

Publikováno v: Journal of Oncology Pharmacy Practice. 29:484-488

Background Interstitial lung disease interstitial lung disease is a group of respiratory diseases that causes progressive fibrosis. Many of the recently approved oncology drugs are associated with the development of interstitial lung disease as an ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e6cd96c6bcffd2f20f44db7cbcccf3
https://doi.org/10.1177/10781552221107532

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Autor: Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydas, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayikcioglu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4603b0dea982cdc71feb0666817cb5
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai